AVNS is no longer listed with the SEC. Avanos Medical, Inc. may have been delisted, renamed or acquired. This report reflects its filing for the period ending 31 Mar 2026 and is kept for reference — last updated .
In short
Avanos Medical, Inc. (AVNS) has net income up 81.4% to -$72.9M and EPS (Diluted) up 81.6% to $-1.57 year on year. Its net margin is -10.4% and gross margin 50.5%. Fisclear flags 1 high-severity risk, led by: Net loss of $72.9M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$24.76
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — AVNS
Inflationary BoomStrengths
EPS (Diluted): $-1.57 (+81.6% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Net Income: -$72.9M (+81.4% YoY) — The company posted a net loss — total expenses exceeded total revenue.
Weaknesses
Operating Cash Flow: $74.7M (-25.8% YoY) — Operating cash flow fell 26% but remained positive.
Gross Profit: $353.9M (-7.2% YoY) — Gross profit declined 7% — costs are growing faster than revenue.
Total Assets: $1.1B (-7.0% YoY) — Total assets shrank 7% — the balance sheet contracted.
Gross margin narrowed by 5.0pp — worth monitoring for further cost pressure.
Stock is near its 52-week high (24.91) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $72.9M — the company spent more than it earned. Investors should monitor the path to profitability.
Year-over-Year Changes
EPS (Diluted)
$-1.57
was $-8.53
Negative EPS — the company recorded a loss on a per-share basis.
Net Income
-$72.9M
was -$392.1M
The company posted a net loss — total expenses exceeded total revenue.
Operating Cash Flow
$74.7M
was $100.7M
Operating cash flow fell 26% but remained positive.
Gross Profit
$353.9M
was $381.3M
Gross profit declined 7% — costs are growing faster than revenue.
Total Assets
$1.1B
was $1.2B
Total assets shrank 7% — the balance sheet contracted.
Risk Flags
1 high · 0 medium · 2 low- ⚠ High
Net loss of $72.9M — the company spent more than it earned. Investors should monitor the path to profitability.
- ○ Low
Gross margin narrowed by 5.0pp — worth monitoring for further cost pressure.
- ○ Low
Stock is near its 52-week high (24.91) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Technical Signals
Daily closes · 1-year dataAvanos Medical, Inc.: common questions
Is Avanos Medical, Inc. profitable?
No. Avanos Medical, Inc. reported a net loss of $73M in its latest fiscal year (fiscal 2025), a net margin of -10.4%.
What is Avanos Medical, Inc.'s P/E ratio?
Avanos Medical, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.
What are the main risks for Avanos Medical, Inc.?
Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Net loss of $72.9M — the company spent more than it earned. Investors should monitor the path to profitability.
Answers are generated from the figures in this report (updated 29 May 2026). Information, not investment advice.
Latest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade AVNS
Links open broker research pages. Not an endorsement or recommendation.
Research Avanos Medical, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.